^
Association details:
| Biomarker: | DNMT3A R882H |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | azacitidine (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response
Published date:
05/25/2021
Excerpt:
Here, we demonstrate that DNMT3AR882H-dependent CH and AML cells are specifically susceptible to the hypomethylating agent azacytidine (AZA). Addition of AZA to chemotherapy prolonged AML survival solely in individuals with DNMT3AR882 mutations, suggesting its potential as a predictive marker for AZA response. AML and CH mouse models confirmed AZA susceptibility specifically in DNMT3AR882H-expressing cells.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1038/s43018-021-00213-9
